Jessica Bzdok

Ms. Jessica Bzdok

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2024 in Genes
Verified
Journal Article
Open access
PDF file
JBJessica Bzdok
Jessica Bzdok
LCLudwig Czibere
Ludwig Czibere
SBSiegfried Burggraf
Siegfried Burggraf
NPNatalie Pauly
Natalie Pauly
EMEsther M. Maier
Esther M. Maier
JDJürgen Durner
Jürgen Durner
Background/Objectives: Genetic newborn screening (NBS) has already entered the phase of common practice in many countries. In Germany, spinal muscular atrophy (SMA), severe combined immunodeficiency (SCID) and sickle cell disease (SCD) are currently a mandatory part of NBS. Here, we describe the experience of six years of genetic NBS including the prevalence of those three diseases in Germany. Methods: Samples and nucleic acids were extracted from dried blood spot cards, commonly used for NBS. A qPCR assay was used to detect disease-causing variants for SMA and SCD, and the detection of T-cell receptor excision circles (TRECs) was performed for SCID screening. Results: The results of the NBS of over 1 million newborns for SMA, approximately 770,000 for SCID and over 410,000 for SCD are discussed in detail. In these newborns, we have identified 121 cases of SMA, 15 cases of SCID and syndrome-based immunodeficiencies and 77 cases of SCD or β-thalassemia. Conclusions: The flexibility of multiplex qPCR is assessed as an effective tool for incorporating different molecular genetic markers for screening. The processing of dried blood spot (DBS) filter cards for molecular genetic assays and the assays are described in detail; turn-around times and cost estimations are included to give an insight into the processes and discuss further options for optimization. The identified cases are in the range expected for the total number of screened newborns, but present a more exact view on the actual prevalences for Germany.

28 June 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JBJessica Bzdok
Jessica Bzdok
LCLudwig Czibere
Ludwig Czibere
SBSiegfried Burggraf
Siegfried Burggraf
OLOlfert Landt
Olfert Landt
EMEsther M. Maier
Esther M. Maier
JDJürgen Durner
Jürgen Durner
Background: Many newborn screening programs worldwide have introduced screening for diseases using DNA extracted from dried blood spots (DBS). In Germany, DNA-based assays are currently used to screen for severe combined immunodeficiency (SCID), spinal muscular atrophy (SMA), and sickle cell disease (SCD). Methods: This study analysed the impact of pre-analytic DNA carry-over in sample preparation on the outcome of DNA-based newborn screening for SCID and SMA and compared the efficacy of rapid extraction versus automated protocols. Additionally, the distribution of T cell receptor excision circles (TREC) on DBS cards, commonly used for routine newborn screening, was determined. Results: Contaminations from the punching procedure were detected in the SCID and SMA assays in all experimental setups tested. However, a careful evaluation of a cut-off allowed for a clear separation of true positive polymerase chain reaction (PCR) amplifications. Our rapid in-house extraction protocol produced similar amounts compared to automated commercial systems. Therefore, it can be used for reliable DNA-based screening. Additionally, the amount of extracted DNA significantly differs depending on the location of punching within a DBS. Conclusions: Newborn screening for SMA and SCID can be performed reliably. It is crucial to ensure that affected newborns are not overlooked. Therefore a carefully consideration of potential contaminating factors and the definition of appropriate cut-offs to minimise the risk of false results are of special concern. It is also important to note that the location of punching plays a pivotal role, and therefore an exact quantification of TREC numbers per μl may not be reliable and should therefore be avoided.

2 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JBJessica Bzdok
Jessica Bzdok
LCLudwig Czibere
Ludwig Czibere
SBSiegfried Burggraf
Siegfried Burggraf
ATArman Tehrani
Arman Tehrani
CCChristiana Cicicopol-Boicu
Christiana Cicicopol-Boicu
EMEsther M. Maier
Esther M. Maier
Metachromatic leukodystrophy (MLD) is a rare inherited lysosomal storage disorder that results from a deficiency of the arylsulfatase A (ARSA) enzyme and leads to progressive neurodegeneration and demyelination. Due to its narrow pre-symptomatic window of opportunity for disease-modifying therapies, the implementation of newborn screening (NBS) for MLD seems crucial and the incorporation of MLD screening into existing NBS programs is required. In many NBS programs, DNA-based assays have already been established, for instance to screen for severe combined immunodeficiency, sickle cell disease, or spinal muscular atrophy. Utilizing these DNA eluates, we established high-multiplex mutation testing (HMMT), a novel DNA-based method, as a genetic first-tier to screen for MLD. By multiplex allele-specific amplification, the assay detects thirteen frequent ARSA variants within the European population identifying newborns with MLD with a modelled, gnomAD-based sensitivity of approximately 92%. Anonymized DNA eluates from 3,078 newborns were tested retrospectively. Variants were identified in nine samples (0.3%) confirmed by an allele-specific differentiation assay and next-generation sequencing. HMMT proved capable to identify frequent ARSA variants as a genetic first-tier test, while panel composition and achievable sensitivity remain to be tested and optimised in a real-world cohort. When biochemical testing cannot be implemented as first tier screening, our approach might be useful to set up as simple screening algorithm for MLD.